Trials / Recruiting
RecruitingNCT06802835
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
EGFR Antibody Combined With Programmed Death-1 Inhibitor and Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Prospective, Multi-center, Phase I/II Clinical Trial
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 148 (estimated)
- Sponsor
- Sun Yat-Sen University Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EGFR Antibody | 6 cycles for combined therapy. Maintenance for 1 year. |
| DRUG | PD-1 antibody | 6 cycles for combined therapy. Maintenance for 1 year. |
| DRUG | Gemcitabine, Cisplatin | 6 cycles for combined therapy. |
| RADIATION | IMRT | IMRT for primary lesion |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2027-02-20
- Completion
- 2029-02-20
- First posted
- 2025-01-31
- Last updated
- 2025-05-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06802835. Inclusion in this directory is not an endorsement.